2. Academic Validation
  3. Hyperalgesic and hypoalgesic mechanisms evoked by the acute administration of CCL5 in mice

Hyperalgesic and hypoalgesic mechanisms evoked by the acute administration of CCL5 in mice

  • Brain Behav Immun. 2017 May;62:151-161. doi: 10.1016/j.bbi.2017.01.014.
Sara González-Rodríguez 1,  Miguel G Álvarez 2,  Mario García-Domínguez 3,  Ana Lastra 4,  Rafael Cernuda-Cernuda 5,  Alicia R Folgueras 6,  María Teresa Fernández-García 7,  Agustín Hidalgo 8,  Ana Baamonde 9,  Luis Menéndez 10
Affiliations

Affiliations

  • 1 Laboratorio de Farmacología, Facultad de Medicina, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, C/ Julián Clavería 6, 33006 Oviedo, Asturias, Spain; Current address S.G-R: Instituto de Biología Molecular y Celular (IBMC), Av. de la Universidad s/n, Edif, Torregaitán, E-03202 Elche, Alicante, Spain. Electronic address: sara.gonzalezr@umh.es.
  • 2 Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, 33006 Oviedo, Asturias, Spain. Electronic address: miguelga_92@hotmail.com.
  • 3 Laboratorio de Farmacología, Facultad de Medicina, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, C/ Julián Clavería 6, 33006 Oviedo, Asturias, Spain. Electronic address: UO201540@uniovi.es.
  • 4 Laboratorio de Farmacología, Facultad de Medicina, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, C/ Julián Clavería 6, 33006 Oviedo, Asturias, Spain. Electronic address: analas2006@hotmail.com.
  • 5 Área de Biología Celular, Departamento de Morfología y Biología Celular, Universidad de Oviedo, INEUROPA (Instituto De Neurociencias Del Principado De Asturias), C/ Julián Clavería 6, 33006 Oviedo, Asturias, Spain. Electronic address: rcernuda@uniovi.es.
  • 6 Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, 33006 Oviedo, Asturias, Spain. Electronic address: arfolgueras@uniovi.es.
  • 7 Unidad de Histopatología Molecular en Modelos Animales de Cáncer, IUOPA, Universidad de Oviedo, C/ Julián Clavería 6, 33006 Oviedo, Asturias, Spain. Electronic address: fernandezgarteresa@uniovi.es.
  • 8 Laboratorio de Farmacología, Facultad de Medicina, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, C/ Julián Clavería 6, 33006 Oviedo, Asturias, Spain. Electronic address: hidalgo@uniovi.es.
  • 9 Laboratorio de Farmacología, Facultad de Medicina, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, C/ Julián Clavería 6, 33006 Oviedo, Asturias, Spain. Electronic address: arbaiza@uniovi.es.
  • 10 Laboratorio de Farmacología, Facultad de Medicina, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, C/ Julián Clavería 6, 33006 Oviedo, Asturias, Spain. Electronic address: luismen@uniovi.es.
PMID: 28126501 DOI: 10.1016/j.bbi.2017.01.014
Abstract

We show here that the intraplantar administration of CCL5 in mice produces hyperalgesia at low doses but activates compensatory antinociceptive mechanisms at doses slightly higher. Thus, the injection of 3-10ng of CCL5 evoked thermal hyperalgesia through the activation of CCR1 and CCR5 receptors, as demonstrated by the inhibitory effect exerted by the selective antagonists J113863 (0.01-0.1μg) and DAPTA (0.3-3μg), respectively. The prevention of this hyperalgesia by diclofenac (1-10μg), the inhibitors of COX-1 SC-560 (0.1-1μg) or COX-2 celecoxib (1-5μg), the TRPV1 antagonist capsazepine (0.03-0.3μg) or the TRPA1 antagonist HC030031 (10-50μg) demonstrates the involvement of prostaglandin synthesis and TRP sensitization in CCL5-evoked hyperalgesia. Doses of CCL5 higher than 17μg did not evoke hyperalgesia. However, this effect was restored by the administration of naloxone-methiodide (5μg), nor-binaltorphimine (10mg/kg) or an anti-dynorphin A antibody (0.62-2.5ng). The administration of 30ng of CCL5 also induced hyperalgesia in mice with reduced number of circulating white blood cells in response to cyclophosphamide or with selective neutrophil depletion induced by an anti-Ly6G antibody. In fact, the number of neutrophils present in paws treated with 30ng of CCL5 was greater than in paws receiving the administration of the hyperalgesic dose of 10ng. Finally, the expression of the endogenous opioid peptide dynorphin A was demonstrated by double immunofluorescence assays in these neutrophils attracted by CCL5. These results support previous data describing the hyperalgesic properties of CCL5 and constitute the first indication that a chemokine of the CC group can activate endogenous analgesic mechanisms.

Keywords

Antinociception; CCL5; Cyclooxygenase; Dynorphin A; Hyperalgesia; Kappa-opioid receptors; Mouse; Neutrophils; TRPA1; TRPV1.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z